The Medwatch panel: Creating future biotech success stories
Future Danish biotech success stories should be created through more advantageous tax conditions, says ALK’s CEO, while Lundbeck’s executive would like to see a more aggresive public investment policy, for example a public investment fund. Strategic partnerships and less attendance to “the law of Jante” are among the other possible solutions identified by this week’s Medwatch panel.
by Kresten Morten Munksgaard
A lack of capital is a recurrent issue when it comes to naming the greatest challenges for the Danish biotech industry. This week the members of the Medwatch panel offer their opinions on how to solve that problem.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
The Medwatch panel: Should all trial data be disclosed?
For abonnenter
The Medwatch panel: Top-execs warn against quick fix
For abonnenter
